|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 mild to moderate meta-analysis
|Li T, 2020|
|RCT||bromhexine||standard of care||COVID-19 mild to moderate||some concern||12/6||safety concern|
|2 studies excluded by filtering options (2 RCT / 0 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).